[
  {
    "ts": "2025-12-03T06:57:38+00:00",
    "headline": "Johnson & Johnson’s (JNJ) Multiple Myeloma Breakthrough Drives Buy Rating From Guggenheim",
    "summary": "Johnson & Johnson (NYSE:JNJ) ranks among the Best Low Volatility Investments in December 2025. On November 25, Guggenheim reaffirmed a Buy rating and $206 price target on healthcare giant Johnson & Johnson (NYSE:JNJ), citing favorable clinical trial findings for its multiple myeloma therapy. The firm noted preliminary data from the MajesTEC-3 trial, which combines Johnson […]",
    "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-multiple-myeloma-065738531.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "761ea6ba-5dc1-38e3-9672-461494167165",
      "content": {
        "id": "761ea6ba-5dc1-38e3-9672-461494167165",
        "contentType": "STORY",
        "title": "Johnson & Johnson’s (JNJ) Multiple Myeloma Breakthrough Drives Buy Rating From Guggenheim",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) ranks among the Best Low Volatility Investments in December 2025. On November 25, Guggenheim reaffirmed a Buy rating and $206 price target on healthcare giant Johnson & Johnson (NYSE:JNJ), citing favorable clinical trial findings for its multiple myeloma therapy. The firm noted preliminary data from the MajesTEC-3 trial, which combines Johnson […]",
        "pubDate": "2025-12-03T06:57:38Z",
        "displayTime": "2025-12-03T06:57:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/000ff4c9b12edba78f9454e5e1cb462e",
          "originalWidth": 700,
          "originalHeight": 525,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/juOPps7.DAlqGqaqLgELRQ--~B/aD01MjU7dz03MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/000ff4c9b12edba78f9454e5e1cb462e.cf.webp",
              "width": 700,
              "height": 525,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Zw.inBgmtGjrav77270FFg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/000ff4c9b12edba78f9454e5e1cb462e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-multiple-myeloma-065738531.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-multiple-myeloma-065738531.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]